Chosa Oncology AB (FRA:W5L)
0.0392
+0.0062 (18.79%)
At close: Nov 18, 2026
Chosa Oncology AB Company Description
Chosa Oncology AB, together with its subsidiaries, engages in developing and commercializing medicines for the treatment of cancer in Sweden and USA.
It provides Platin-DRP, a multigene mRNA-based algorithm that predicts a patient’s response to platinum-based chemotherapy; and LiPlaCis, a liposomal formulation of cisplatin, enabling delivery of chemotherapy agent directly to tumor sites.
The company was formerly known as Chosa ApS. Chosa Oncology AB was incorporated in 2015 and is based in Malmö, Sweden.
Chosa Oncology AB
| Country | Sweden |
| Founded | 2015 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 2 |
| CEO | Peter Jensen |
Contact Details
Address: Kungsgatan 6 Malmö, 211 49 Sweden | |
| Phone | 45 2 16 08 922 |
| Website | chosaoncology.com |
Stock Details
| Ticker Symbol | W5L |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0007784319 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Peter Jensen | Chief Executive Officer |
| Gerton Jonsson | Chief Financial Officer |
| Ulla Buhl | Chief Operating Officer |